Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Paul F. Bray
Dr Paul F. Bray is a clinician-scientist with an academic interest in bleeding and clotting disorders. His Hematology-Oncology training was at the University of California in San Francisco (UCSF) and joined the Hematology faculty at Johns Hopkins University School of Medicine in 1990. In 2000 he was recruited to Baylor College of Medicine as the first Chief of a new Section of Thrombosis Research. In 2006, Dr Bray became the 6th Director of the Cardeza Foundation for Hematologic Research and Director of Hematology at Thomas Jefferson University. In late 2016, Dr Bray return to his roots, and joined the Division of Hematology and Hematologic Malignancies and the Molecular Medicine Program at the University of Utah as a Professor in the Department of Internal Medicine. Dr Bray has served in numerous national and international advisory positions, NIH review panels and committees for the American Society of Hematology and the International Society of Thrombosis and Haemostasis (ISTH). He was an Investigator in the Women's Health Initiative from 2000–2008 and is a charter member and co-Chair of the ISTH Scientific Subcommittee Genomics in Thrombosis and Hemostasis. Dr Bray has over 30 years of experience in the molecular genetics and cell biology of platelets, with a long research interest in arterial thrombosis and has expertise in platelet molecular biology, genetics, RNA expression, microRNAs, genomics and functional characterization of genetic variants. He has had 34 years of continuous funding from the National Institutes of Health (NIH) and has published more than 175 peer-reviewed papers, book chapters and invited reviews. He has trained more than 30 postdoctoral fellows, graduate students, Heme/Onc fellows and junior faculty. Throughout his career, Dr Bray has continued to care for patients with blood diseases.
Dr Borhane Guezguez is a group leader at the German Cancer Research Center (DKFZ) in Heidelberg and associate member of the Department of Hematology and Oncology at the University Medical Center in Mainz. He earned his M.S. and PhD diploma in Molecular and Cell Biology in 2006 from Pierre and Marie Curie University (Paris, France) under co-supervision of Dr. Dominique Dunon and Dr Thierry Jaffredo where he was mentored and gained expertise in vertebrae hematopoiesis during early embryonic development. He pursued his post-doctoral training and academic teaching (2007–2016) in the laboratory of Dr. Mickie Bhatia at McMaster University in Canada focusing on Hematopoietic Stem Cell Biology, the process of leukemogenesis and Experimental Hematology. In the Spring of 2017, he joined the German Cancer Research Center (DKFZ) as group leader in translational research as part of the German Cancer Consortium (DKTK) within the Department of Hematology and Oncology at the University Medical Center in Mainz.
Dr Guezguez has published 15 primary research articles and 6 reviews/editorials/book chapters with his current main research focusing on identifying the molecular and epigenetic stem cell regulatory processes that govern hematological malignancies (MDS, AML), tumor microenvironment and immune escape; with the aim for development of novel therapeutic strategies for leukemia treatment and regenerative medicine.